A Phase 0, Open-Label, Multi-Center, Observational Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept.
Phase of Trial: Phase 0
Latest Information Update: 28 Nov 2011
At a glance
- Drugs Abatacept (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Astellas Pharma
- 28 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Sep 2011 Planned end date changed from Sep 2011 to Oct 2011 as reported by ClinicalTrials.gov.
- 29 Jul 2011 Planned end date changed from Jul 2011 to Sep 2011 as reported by ClinicalTrials.gov.